Cancer
Malignant Prostate Neoplasm
CI-CAN-00005927Explore in graph →
Top-level1,377 active trials24 approved drugs58 evidence items
- NCIt
- C7378
- ICD-10
- C61
- DOID
- 10283
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005927Explore in graph →
Clinical trials
5,981 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (730)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06398470 | Study to Evaluate a New Method to Detect Residual Tumours During Surgery for Prostate Cancer Using Confocal Microscopy | completed | Phase 1 / Phase 2 | 21 | University College, LondonOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT02920229 | 68Ga-PSMA HBED-PET/CT in the Evaluation of the Biochemical Relapse in Patients With a History of Prostate Cancer Radically Treated(GaPSMA) | completed | N/A | 1,230 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER |
| 1 |
| Jan 9, 2025 |
| clinicaltrials |
| NCT04775602 | Experimental Study to Evaluate the Impact of 18 Fluoro-PSMA (18F-PSMA) PET / CT in the Management of Patients with Prostate Cancer.(F-PSMA) | completed | Phase 2 | 550 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT05612880 | Physical Function During ARSI Treatment | completed | — | 24 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT02643667 | Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer | completed | Phase 2 | 27 | Washington University School of MedicineOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT03454750 | Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC)(LU-PSMA) | completed | Phase 2 | 143 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT02050906 | Intensive Diet and Exercise or Standard of Care in Improving Physical Function and Quality of Life in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy(IDEA-P) | completed | N/A | 32 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT05146973 | External Beam Therapy With Theranostic Radioligand Therapy for Oligometastatic Prostate Cancer (ProstACT TARGET) | completed | Phase 2 | 5 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | Dec 19, 2024 | clinicaltrials |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment(ROOT) | completed | — | 167 | Taproot HealthINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT01784913 | A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer(UV1/hTERT2012P) | completed | Phase 1 / Phase 2 | 22 | Ultimovacs ASAINDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT03232164 | PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer | completed | Early Phase 1 | 126 | University of Wisconsin, MadisonOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT03002220 | Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status(EXCAAPE) | completed | Phase 2 | 52 | MedSIROTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT01650194 | A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients | completed | Phase 2 | 60 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Dec 10, 2024 | clinicaltrials |
| NCT02218606 | Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer | completed | Phase 2 | 81 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT02362464 | Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139 | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Dec 10, 2024 | clinicaltrials |
| NCT05079828 | Head-to-head Comparison of 68Ga-PSMA-11 and 18F-PSMA-1007 | completed | N/A | 100 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT06726070 | Investigation of the Diagnostic Role of miRNAs in PCa and BPH | completed | — | 57 | Alanya Alaaddin Keykubat UniversityOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT02220829 | Comparative Study of Use of Alpha-Blockers to Treat Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy | completed | Phase 3 | 148 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT02918968 | Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer | completed | Phase 4 | 206 | Astellas Pharma IncINDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT01534052 | A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100 | completed | Phase 2 | 52 | Astellas Pharma IncINDUSTRY | 3 | Dec 6, 2024 | clinicaltrials |
| NCT01977651 | A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide(UPWARD) | completed | Phase 4 | 424 | Astellas Pharma Global Development, Inc.INDUSTRY | 20 | Dec 6, 2024 | clinicaltrials |
| NCT02116582 | A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer | completed | Phase 4 | 215 | Astellas Pharma Europe B.V.INDUSTRY | 5 | Dec 6, 2024 | clinicaltrials |
| NCT02799745 | A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance(ENACT) | completed | Phase 2 | 227 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Dec 6, 2024 | clinicaltrials |
| NCT06714227 | Genetics of Prostate Cancer in Young Patients(ProK55) | completed | — | 50 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT03707184 | Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone | completed | Phase 2 | 17 | University of UtahOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT03035032 | A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients | completed | Phase 4 | 107 | Astellas Pharma Singapore Pte. Ltd.INDUSTRY | 8 | Nov 26, 2024 | clinicaltrials |
| NCT02366494 | Micro RNAs to Predict Response to Androgen Deprivation Therapy | completed | — | 42 | Medical College of WisconsinOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT03350529 | MRI Guided Transurethral HIFU for Various Prostate Diseases(HIFU-PRO) | completed | N/A | 87 | Turku University HospitalOTHER_GOV | 1 | Nov 25, 2024 | clinicaltrials |
| NCT05438524 | The Performance of MRI Prostate in Men With Different Prostate Health Index (Phi) Values | completed | — | 159 | Chinese University of Hong KongOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT01284920 | A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients | completed | Phase 1 / Phase 2 | 47 | Astellas Pharma IncINDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT02124668 | A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | completed | Phase 2 | 30 | Astellas Pharma Europe B.V.INDUSTRY | 2 | Nov 21, 2024 | clinicaltrials |
| NCT02669771 | Long-Term Specified Drug Use-Results Survey for Xtandi Capsule | completed | — | 1,018 | Astellas Pharma IncINDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT02787005 | Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199) | completed | Phase 2 | 388 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 21, 2024 | clinicaltrials |
| NCT03328364 | A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden | completed | — | 211 | Astellas Pharma a/sINDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT05381311 | Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study | completed | — | 1,020 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT02380274 | Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)(TRUMPET) | completed | — | 1,030 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT03248570 | Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects | completed | Phase 2 | 26 | University of California, San FranciscoOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT04094519 | A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer | completed | Phase 1 | 24 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06362291 | Comparison of MRI AI-cTB Versus Routine cTB in Prostate Cancer Diagnosis: a Prospective Randomized Controlled Trial | completed | N/A | 380 | Peking University First HospitalOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT03535987 | Pilot Cohort Study of Rb-82 Myocardial PET Imaging to Evaluate Coronary Microvascular Dysfunction in Men With Prostate Cancer Receiving Androgen-Deprivation Therapy | completed | — | 18 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05064670 | Exercise as Medicine for People With Cancer Sweden(EX-MED) | completed | N/A | 200 | Karolinska InstitutetOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT02213107 | Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer. | completed | Phase 2 | 43 | University of RochesterOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT03414034 | Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 72 | Cardiff OncologyINDUSTRY | 1 | Nov 7, 2024 | clinicaltrials |
| NCT01325506 | Effectiveness of Open and Robotic Prostatectomy(PROSTQA-RP2) | completed | — | 677 | Beth Israel Deaconess Medical CenterOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT03128710 | Prostate Cancer Survey | completed | — | 224 | University of Maryland, BaltimoreOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT05715827 | A Prospective, Single-center, Single-arm, Pivotal Trial of the Medtronic Hugo™ Robotic Assisted Surgery (RAS) System | completed | — | 42 | Medtronic - MITGINDUSTRY | 1 | Nov 5, 2024 | clinicaltrials |
| NCT05895279 | Assessment of Research Digest Impact for Minority with Prostate Cancer, MiCAP Phase III Study(MiCaP) | completed | N/A | 220 | Mayo ClinicOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT05498623 | MR Fingerprinting for Diagnostic of Prostate Cancer | completed | — | 203 | Norwegian University of Science and TechnologyOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT05759273 | A Study to Observe Demography and the Outcome of Prostate Cancer Patients Treated With 6-month Triptorelin Formulation in Italy(REAL6T) | completed | — | 167 | IpsenINDUSTRY | 1 | Nov 1, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jan 10, 2025source: clinicaltrials